You are here: Industry Insights > Kura Oncology

News List

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib americanpharmaceuticalreview
March 01, 2021
Kura Oncology announced its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and ...
Kura Oncology Reports Data from Tipifarnib Trial in Head and Neck Squamous Cell Carcinoma americanpharmaceuticalreview
June 08, 2020
Kura Oncology announced updated clinical outcome data from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy.
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas americanpharmaceuticalreview
March 06, 2020
Kura Oncology announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib ...
Kura Oncology Announces Chief Commercial Officer Appointment americanpharmaceuticalreview
January 13, 2020
Kura Oncology announced the appointment of Kirsten Flowers as Chief Commercial Officer. Flowers joins Kura most recently from Array Biopharma, where she served as head of commercial operations until the completion of its $11.4 billion acquisition by Pfize